The record
| Class | glp1 agonist |
|---|---|
| Also known as | Byetta, Bydureon, Exendin-4, AC2993 |
| Chain length | - |
| Molecular weight | 4,186.6 Da |
| Half-life | 2.4 hours (IR); extended with ER microspheres |
| Route | SC |
| Studied for | Type 2 diabetes mellitus; Weight management (off-label); NASH/fatty liver (investigational) |
| Research use | GLP-1 signaling, beta cell preservation, neuroprotection research |
| What has been shown | HbA1c reduction: 0.8-1.1% (IR), up to 1.5% (ER); Weight loss: 2-4 kg typical; Beta cell function improvement; Postprandial glucose control |
| How it works | Synthetic version of exendin-4 from Heloderma suspectum (Gila monster) saliva. 39-amino acid incretin mimetic with 53% homology to human GLP-1 but resistant to DPP-4. Binds GLP-1R with high affinity, activating adenylyl cyclase. The C-terminal "Trp cage" (PSSGAPPPS) provides enhanced stability and receptor binding. |
| Patent status | AstraZeneca |
| Regulatory status | FDA approved 2005/2012 |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Glucose Regulation Support (affection, 82%)
- Cardiovascular risk reduction in T2DM (illness, 60%)
- CV risk reduction in T2D with CVD (illness, 40%)
- NASH/fatty liver (illness, 100%)
- Type 2 diabetes (illness, 40%)
- Type 2 diabetes mellitus (illness, 100%)
- Weight management (illness, 100%)
- High blood sugar (symptom, 100%)